CION Ameerpet
Kidney cancer — most commonly renal cell carcinoma (RCC) — is one of the few cancers where early detection leads to cure in the vast majority of cases. Many tumours are caught incidentally on imaging, giving patients a treatment advantage when they act with the right specialist team. At CION Cancer Clinics, our surgical, medical and radiation oncology team delivers the full spectrum of kidney cancer care — from nephron-sparing surgery and laparoscopic nephrectomy to the latest NCCN-approved combination immunotherapy for advanced disease.
Kidney cancer develops when cells in the kidney begin to grow uncontrollably, forming a tumour. Renal cell carcinoma (RCC) is the most common type, accounting for approximately 85% of all kidney cancers in adults. The remaining 15% include urothelial carcinoma of the renal pelvis, rare sarcomas, and in children, Wilms tumour (nephroblastoma).
Hyderabad's rising rates of hypertension, obesity, and Type 2 diabetes — all recognised risk factors for RCC — are contributing to increasing kidney cancer incidence across the city. The encouraging reality is that kidney cancer detected at Stage I or II has five-year survival rates exceeding 90%, and many patients are cured with surgery alone.
The choice of treatment centre matters considerably — particularly for decisions around nephron-sparing surgery, access to current immunotherapy combinations, and coordination of robotic surgical referral when minimally invasive techniques beyond standard laparoscopy are required.
Not every kidney cancer behaves the same way. CION's tumour board evaluates each patient's diagnosis at the cellular and molecular level so treatment is matched precisely to the subtype.
The dominant form of kidney cancer in adults. RCC develops in the proximal renal tubules — the small filtering tubes of the kidney — and is further classified by cell type:
Develops in the transitional cells lining the renal pelvis — the funnel-shaped structure where urine collects before passing to the ureter. Treated similarly to bladder cancer with nephroureterectomy and chemotherapy, with long-term surveillance for bladder recurrence.
A paediatric kidney cancer occurring predominantly in children under 5 years. Highly chemosensitive and curable in the majority of cases with a combination of neoadjuvant chemotherapy, surgery, and radiation therapy where required. Managed through CION's paediatric oncology pathway.
Approximately 5–8% of kidney cancers are hereditary:
CION offers genetic counselling for patients with early-onset, bilateral, or familial kidney cancer.
Understanding your personal risk is critical — particularly with Hyderabad's rising rates of hypertension, obesity, and Type 2 diabetes, all of which are linked to RCC.
If you have any of these risk factors, an abdominal ultrasound during routine check-ups is a low-cost way to catch a tumour early — before symptoms appear.
Kidney cancer is often called a 'silent' tumour — the classic triad of symptoms (blood in urine, flank pain, and palpable abdominal mass) occurs together in fewer than 10% of patients, and many early-stage tumours produce no symptoms at all. Signs to be aware of include:
If you notice blood in the urine — even once — consult a specialist immediately. Haematuria is never normal and warrants prompt investigation. Speak to a CION kidney cancer oncologist if you have symptoms or known risk factors.
Sixteen reasons our patients pick CION — nephron-sparing surgery as default, active surveillance, genetic counselling, and full integrative support.
1,000+ kidney cancer cases
7 locations across Hyderabad
5-Star NABH Accredited
NCCN Protocol Adherence
Nephron-sparing surgery as default
Laparoscopic nephrectomy
Robotic-assisted nephrectomy referral
Active surveillance programme
Genetic counselling
Multidisciplinary tumour board review
Full integrative support
Dedicated Second Opinion service
Aarogyasri empanelled
EMI facility
4.8 / 5 Google rating
35+ centres across Telangana & AP
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Our multidisciplinary tumour board reviews your imaging and pathology — especially important when kidney-sparing surgery may be an option you have not yet been offered.
Kidney cancer diagnosis is primarily imaging-driven. Unlike most other cancers, biopsy is not routinely required — the imaging characteristics of kidney tumours on CT or MRI are often sufficient for diagnosis. CION's diagnostic pathway is streamlined to reach a treatment decision efficiently.
Renal mass biopsy is performed selectively at CION — not routinely. It is indicated when imaging is indeterminate, when a small renal mass is being considered for active surveillance, or when metastatic disease needs histological confirmation before systemic therapy. Image-guided core needle biopsy is used where indicated.
Kidney cancer is staged using the TNM (Tumour, Node, Metastasis) system. Stage directly determines the treatment approach. The table below maps clinical stages to standard treatment options as per current NCCN guidelines.
| Stage | Tumour Status | Lymph Nodes / Metastasis | Primary Treatment |
|---|---|---|---|
| Stage I | Tumour ≤7cm, confined to kidney (T1) | No nodes, no metastasis | Partial or radical nephrectomy; active surveillance for T1a <4cm in select patients |
| Stage II | Tumour >7cm, confined to kidney (T2) | No nodes, no metastasis | Radical nephrectomy; partial nephrectomy where technically feasible |
| Stage III | Extends into major veins or perinephric tissue (T3); or regional lymph nodes (N1) | Regional nodes only | Radical nephrectomy + lymph node dissection; adjuvant pembrolizumab for high-risk resected RCC |
| Stage IV | Extends beyond Gerota's fascia (T4) or distant metastasis (M1) | Any N, M1 | Cytoreductive nephrectomy (select cases) + systemic therapy; or systemic therapy alone |
Treatment decisions are always individualised by CION's multidisciplinary tumour board based on performance status, renal function, risk stratification, and patient preference.
CION follows NCCN protocol-driven treatment planning for all kidney cancer subtypes. Every case is reviewed by a multidisciplinary tumour board before treatment begins.
Surgery is the cornerstone of curative kidney cancer treatment. CION prioritises nephron-sparing approaches wherever oncologically appropriate — preserving kidney function and reducing the long-term risk of chronic kidney disease.
Robotic-assisted surgery offers enhanced precision and three-dimensional visualisation for complex partial nephrectomies — particularly for hilar tumours or those requiring intricate reconstruction. CION does not perform robotic surgery in-house. Patients who are candidates are referred to accredited robotic centres, while CION coordinates the complete journey — pre-surgical workup, referral, and post-operative oncology follow-up.
Not every kidney tumour requires immediate surgery. For T1a tumours (under 4cm) — particularly elderly patients, those with significant comorbidities, or those with a single kidney — active surveillance is a recognised NCCN management option. CT or MRI every 3–6 months monitors growth; intervention is triggered only by meaningful progression. CION is one of the few oncology networks in Hyderabad to formally offer this pathway.
Radiofrequency Ablation (RFA) uses heat generated by electrical current to destroy small kidney tumours (T1a, <4cm) in patients unsuitable for surgery. Cryoablation delivers extreme cold via a probe to freeze and destroy tumour tissue. Both are image-guided, minimally invasive, and effective for small peripheral renal masses.
The kidney is a relatively radiation-sensitive organ and conventional radiation has a limited role in primary RCC. CION uses advanced techniques in specific situations:
For advanced or metastatic RCC, CION delivers all current NCCN preferred regimens — including combination immunotherapy (detailed in the next section), targeted oral TKIs (sunitinib, pazopanib, cabozantinib), and mTOR inhibitors (everolimus) for second-line and beyond. Adjuvant pembrolizumab is the recommended option following resection of high-risk Stage II or Stage III RCC per the Keynote-564 trial.
The treatment of advanced and metastatic RCC has been transformed by combination immunotherapy. Single-agent sunitinib — once the standard of care — has now been largely replaced by combination regimens demonstrating superior survival. CION delivers current NCCN preferred protocols.
The combination of nivolumab (PD-1 inhibitor) and ipilimumab (CTLA-4 inhibitor) is an NCCN preferred first-line regimen for intermediate and poor-risk advanced RCC. The CheckMate-214 trial demonstrated significantly improved overall survival and complete response rates compared to sunitinib — with durable responses persisting after treatment completion. CION administers this regimen with regular immune-related adverse event monitoring throughout treatment.
The combination of pembrolizumab (PD-1 inhibitor) and axitinib (VEGFR tyrosine kinase inhibitor) is an NCCN preferred first-line regimen for advanced RCC across all risk groups. The Keynote-426 trial demonstrated superior overall survival and progression-free survival versus sunitinib across all IMDC risk groups. This combination provides both immune activation and anti-angiogenic tumour suppression simultaneously.
Kidney cancer management requires close coordination between surgical oncology, medical oncology, radiation oncology, and where appropriate, genetic counselling. At CION, every kidney cancer case is reviewed by a multidisciplinary tumour board ensuring:
Treatment costs vary based on cancer stage, surgical approach, and whether systemic therapy is required. The ranges below are indicative — CION provides a personalised cost estimate after your initial oncology consultation.
| Treatment | Approx. Cost (INR) | Notes |
|---|---|---|
| Partial Nephrectomy (Laparoscopic) | ₹2,00,000 – ₹4,50,000 | Preferred for T1 tumours; shorter hospital stay |
| Radical Nephrectomy (Laparoscopic) | ₹2,50,000 – ₹5,00,000 | Varies by extent of lymph node dissection |
| Radical Nephrectomy (Open) | ₹2,00,000 – ₹4,00,000 | For complex or large tumours |
| Ablation (RFA / Cryoablation) | ₹75,000 – ₹2,00,000 | Day-care procedure for small tumours |
| Targeted Therapy (per month) | ₹25,000 – ₹1,20,000 | Sunitinib / pazopanib oral; long-term maintenance |
| Combination Immunotherapy (per cycle) | ₹1,50,000 – ₹3,50,000+ | Nivolumab + ipilimumab / pembrolizumab + axitinib |
| Radiation Therapy (SBRT) | ₹1,50,000 – ₹3,00,000 | Per treatment course for oligometastatic disease |
| Full Multi-modal Treatment | ₹2,00,000 – ₹8,00,000+ | Depending on stage and treatment sequence |
1,000+ cancer cases treated yearly. Decisions made by a tumour board, not a single doctor. Costs explained upfront, every time.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Common questions about kidney cancer treatment in Hyderabad — answered by CION's oncology team.
Disclaimer: This content is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified oncologist for guidance specific to your medical condition. The information on this page is periodically reviewed and updated by CION's medical team in accordance with current clinical guidelines.